ArticleFrontiers in oncology2022
[
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas.Frontiers in medicine · 2025Pooled it
- PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: insights from a prospective PET-MRI guided multiregional biopsy study.European journal of nuclear medicine and molecular imaging · 2025Trial
- PSMA-Targeted Theranostics in Glioblastoma Multiforme: Current Evidence and Future Perspectives.International journal of molecular sciences · 2026Review
- Prostate-Specific Membrane Antigen Expression in Colorectal Cancer and Its Potential Implication in Disease Monitoring in Rectal Cancer.Journal of gastrointestinal cancer · 2025Article
- Evaluating the Potential of PSMA Targeting in CNS Tumors: Insights from Large-Scale Transcriptome Profiling.Cancers · 2025Article
- Precision radiotherapy with molecular-profiling of CNS tumours.Journal of neuro-oncology · 2025Review
- Do we need dosimetry for the optimization of theranostics in CNS tumors?Neuro-oncology · 2024Review
- Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?Bioengineering (Basel, Switzerland) · 2024Review
- Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [EJNMMI radiopharmacy and chemistry · 2024Article
- Impact of [Cancers · 2023Article
- PSMA-targeted therapy for non-prostate cancers.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: High-grade gliomas (HGG) are still associated with a dismal prognosis. Prostate specific membrane antigen (PSMA) is discussed as a theranostic target for PSMA-directed radioligand therapy ([ Methods: Patients with relapsing HGG underwent [ Results: We included 20 patients with a median age of 53 years (IQR 42-57). The median SUV on [ Conclusion: Only a minority of patients with relapsing HGG qualified for [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.